This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Pramlintide released from the silica depot maintained a steady serum concentration of 500 pM for 60 days.
Why it matters
This method could improve diabetes treatment by reducing the need for frequent dosing and minimizing hypoglycemia risks. It represents a significant advancement in drug delivery technology.
How the study worked
The study involved formulating a silica microparticle hydrogel depot and testing its drug release in a rat model.
What this study cannot tell us
The study was conducted in rats, and results may not directly translate to humans. Further studies are needed to assess safety and efficacy in human subjects.
Read the original research
Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, Pramlintide.
Pharmaceutics, 14(3)
Citation
Tyagi, Puneet; Koskinen, Mika; Mikkola, Jari; Sarkhel, Sanjay; Leino, Lasse; Seth, Asha; Madalli, Shimona; Will, Sarah; Howard, Victor G; Brant, Helen; Corkill, Dominic. (2022). Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, Pramlintide.. Pharmaceutics, 14(3). https://doi.org/10.3390/pharmaceutics14030553